NCT02200081View on ClinicalTrials.gov

Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

October 5, 2017

Conditions
Small Cell Lung Cancer
Interventions
DRUG

MGN1703

OTHER

Standard of care

Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other

Trial Locations (4)

6020

Medizinische Universitaet Innsbruck, Innsbruck

9000

Universitair Ziekenhuis Gent, Ghent

28040

Hospital Universitario Fundación Jiménez Díaz, Madrid

69126

Thoraxklinik Heidelberg gGmbH, Heidelberg

Sponsors

Lead Sponsor

Mologen AG
All Listed Sponsors
lead

Mologen AG

INDUSTRY

NCT02200081 - Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC | Biotech Hunter | Biotech Hunter